Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 901 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength Could Functional Precision Medicine Be the New Precision Oncology? Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL MOST POPULAR Forging Military Partnerships to Empower the Cancer Research Enterprise March 27, 2018 A radical project: video game design meets cancer research December 1, 2022 Metastatic Breast Cancer: ESMO Clinical Practice Guideline May 29, 2026 Healthy 33-Year-Old Nurse Learned She Had Cervical Cancer and Breast Cancer... April 30, 2019 Load more HOT NEWS FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL 11 top tips for cutting back on alcohol Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’
